Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
Healthcare
$6.21 +1.11%
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
52W Low $4.19High $9.32
Volume 1.21M
Average 0.22M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$29.03M
FY 2025 · Annual
Investing Cash Flow
-$598,767.00
FY 2025 · Annual
Financing Cash Flow
$77.33M
FY 2025 · Annual
+68.9% YoYCash Flow Statement
Mixed currencies
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (18.18M) | (18.99M) | (21.81M) | (25.74M) | (39.22M) |
| Depreciation & Amortization | 88.17K | 147.89K | 117.1K | 171.72K | 241.68K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 1.43M | 1.06M | 3.22M | 0 |
| Change in Working Capital | (167.16K) | 1.51M | 4.03M | (6.76M) | (725.6K) |
| Accounts Receivables | 150.92K | 230.48K | (78.09K) | (101.39K) | (438.64K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.32M | 435.12K | (714.88K) | 2.4M |
| Other Working Capital | (318.07K) | (39.96K) | 3.67M | (5.95M) | (2.69M) |
| Other Non-Cash Items | 6.68M | 1.5M | 977.18K | (880.5K) | 10.68M |
| Operating Cash Flow | (11.58M) | (14.4M) | (15.62M) | (29.99M) | (29.03M) |
| Capital Expenditures | (341.28K) | (235.55K) | (55.25K) | (104.23K) | (598.77K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.12M) | (3.27M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 13.34M | 0 | 0 | 0 |
| Other Investing Activities | (3.97M) | 242 | 0 | 29.07K | 0 |
| Investing Cash Flow | (11.42M) | 9.83M | (55.25K) | (75.16K) | (598.77K) |
| Debt Repayment | 9.62M | (142.27K) | (59.81K) | (9.14M) | 0 |
| Common Stock Issued | 29.91M | 10.64M | 11.96M | 54.56M | 77.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (69.33K) | 306.77K | 3.97M | 363.06K | 0 |
| Financing Cash Flow | 39.46M | 10.8M | 15.87M | 45.78M | 77.33M |
| Effect of Forex Changes | (63.69K) | (507.4K) | 618.45K | (1.96M) | (403.1K) |
| Net Change in Cash | 16.4M | 5.73M | 811.93K | 13.76M | 47.3M |
| Free Cash Flow | (11.92M) | (14.63M) | (15.68M) | (30.1M) | (29.63M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.2M
+ D&A$241.7K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$725.6K
+ Other Non-Cash$10.7M
= Operating Cash Flow-$29.0M
- Capex-$598.8K
= Free Cash Flow-$29.6M
Analysis
FY2025 free cash flow is -$29.6M. FCF conversion is 75.5% of net income. Operating cash flow was -$29.0M, with capex of -$598.8K. The largest bridge item is Other Non-Cash at $10.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 | |
| 6-K | 6-K filing | Nov 10, 2026 |
Does EPRX generate free cash flow?
Eupraxia Pharmaceuticals Inc. (EPRX) generated -$29.63M of free cash flow in fiscal 2025.
How much operating cash flow does EPRX produce?
Operating cash flow was -$29.03M, before capital expenditures of $598,771.00.
Continue the stock analysis
Jump to another research area for this company.